Abstract
PRS35 - Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have